Blueprint Medicines (BPMC) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Blueprint Medicines Corporation  (NASDAQ: BPMC)

Blueprint Medicines's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Blueprint Medicines in the first quarter 2025?
Blueprint Medicines Corporation recorded a cumulative net loss of $-156 million during 12 months ending in the first quarter 2025, resulting in a negative return on equity (ROE) of -48.89%.

Within the Major Pharmaceutical Preparations industry 160 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2024 from 1873 to 3040.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change 10.12 % 128.67 % 54.56 % 2.93 % -
Y / Y Net Income Change -99.44 % - - - -
Net Income (TTM) in Millions -156 -67 -128 -205 -288
Return On Equity (TTM) -48.89 % -21.59 % -47.66 % -85.25 % -120.74 %
BPMC's Total Ranking # 3040 # 1873 # 2549 # 2431 # 2617
Equity (TTM) in Millions 342 299 313 320 311
Seq. Equity Change 14.55 % -4.62 % -2.21 % 3.08 % 137.88 %
Seq. Net Income Change - - - - -

Back to BPMC Management Effectiveness >> BPMC's 5 Years Annual ROE >> Compare BPMC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 161
Sector # 403
Overall # 3040

Return On Equity Statistics
High Average Low
40.89 %
-58.98 %
-191.56 %
(Sep 30 2020)   (Dec 31 2023)





BPMC Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 299 131 515 971 1,470
Y / Y Equity Change 128.67 % -74.62 % -46.98 % -33.97 % 216.58 %
Net Income in Millions -67 -507 -558 -644 314
Y / Y Net Income Change - - - - -
Return On Equity -22.46 % -388.17 % -108.32 % -66.35 % 21.35 %

Back to BPMC Management Effectiveness >> BPMC's 5 Years Annual ROE >> Compare BPMC ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BPMC's' Return on Equity at Yahoo Finance
BPMC's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BPMC's Competitors
Subscribers only: Roe for Blueprint Medicines's Suppliers
Subscribers only: Return On Equity for BPMC's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE

Date modified: 2026-09-08T16:52:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.